We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-14.95%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.72B
AUM Growth
-$950M
Cap. Flow
-$368M
Cap. Flow %
-21.39%
Top 10 Hldgs %
48.56%
Holding
373
New
67
Increased
88
Reduced
111
Closed
78

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$59.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$32.9M
3
AMGN icon
Amgen
AMGN
+$18M
4
LLY icon
Eli Lilly
LLY
+$15.9M
5
BMY icon
Bristol-Myers Squibb
BMY
+$7.23M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$6.04M
2
ABT icon
Abbott
ABT
+$4.77M
3
RGNX icon
Regenxbio
RGNX
+$4.1M
4
CELG
Celgene Corp
CELG
+$3.94M
5
UTHR icon
United Therapeutics
UTHR
+$3.59M

Sector Composition

Rank Sector Weight
1 Healthcare 17.88%
2 Financials 0.23%
3 Consumer Staples 0.05%
4 Technology 0.03%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RXIIW
201
DELISTED
RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021
RXIIW
$454K 0.03%
+2,270,283
New +$409K
VCEL icon
202
Vericel Corp
VCEL
$2.35B
$450K 0.03%
+149,900
New +$385K
XTLB
203
XTL Biopharmaceuticals
XTLB
$6.66M
$434K 0.03%
36,207
-1,357
-4% -$20.6K
ONTXW
204
DELISTED
Onconova Therapeutics, Inc. Warrants
ONTXW
$428K 0.02%
691,072
-34,362
-5% -$30.8K
CVM icon
205
CEL-SCI Corp
CVM
$20.4M
$427K 0.02%
8,480
+3,983
+89% +$611K
ISEE
206
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$426K 0.02%
883
-634
-42% -$18.8K
IMNN icon
207
Imunon
IMNN
$6.43M
$416K 0.02%
487
+160
+49% +$365K
WINT
208
DELISTED
Windtree Therapeutics Inc
WINT
$415K 0.02%
334,414
+24,414
+8% +$45.1K
BLPH
209
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$414K 0.02%
+52,657
New +$733K
TXMD icon
210
CALL
TherapeuticsMD
TXMD
$23.7M
$406K 0.02%
14
-24
-63% -$7.44K
CLRB icon
211
Cellectar Biosciences
CLRB
$20.5M
$395K 0.02%
+108
New +$586K
TGTX icon
212
PUT
TG Therapeutics
TGTX
$8.28B
$394K 0.02%
+848
New +$4.97K
BNTC icon
213
Benitec Biopharma
BNTC
$404M
$389K 0.02%
998
-79
-7% -$30.1K
GNVC
214
DELISTED
GenVec, Inc.
GNVC
$387K 0.02%
120,544
-30,494
-20% -$106K
DXTR
215
DELISTED
Dextera Surgical Inc.
DXTR
$382K 0.02%
397,863
-52,644
-12% -$79.3K
STML
216
CALL
DELISTED
Stemline Therapeutics, Inc.
STML
$381K 0.02%
356
+134
+60% +$1.62K
CMRX
217
DELISTED
Chimerix, Inc.
CMRX
$368K 0.02%
79,900
– –
CBMXW
218
DELISTED
CombiMatrix Corporation Warrant
CBMXW
$363K 0.02%
844,917
-12,829
-1% -$7.57K
EYPT icon
219
EyePoint Inc
EYPT
$988M
$351K 0.02%
20,510
+1,000
+5% +$20.3K
AMRN
220
PUT
Amarin Corp
AMRN
$298M
$344K 0.02%
56
– –
TXMD icon
221
PUT
TherapeuticsMD
TXMD
$23.7M
$338K 0.02%
12
– –
ASRT
222
CALL
DELISTED
Assertio
ASRT
$335K 0.02%
3
-69
-96% -$87.9K
IMUC
223
DELISTED
ImmunoCellular Therapeutics, Ltd.
IMUC
$328K 0.02%
160,129
-2
-0% -$6
BIOC
224
DELISTED
Biocept, Inc.
BIOC
$319K 0.02%
+46
New +$385K
KPRX icon
225
Kiora Pharmaceuticals
KPRX
$11.3M
$314K 0.02%
36
-58
-62% -$507K
7 8
9
10 11

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2016 Portfolio in Review

As of Q4 2016, Sabby Management held 373 positions worth $1.72B, down 36% from $2.67B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Sabby Management withdrew a net $368M in Q4 2016, closing 78 positions and reducing 111 holdings. Its most notable exit was Shire pic, an estimated $6.04M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 9.2% a quarter earlier, followed by Financials and Consumer Staples.

Against the trend, Sabby Management opened a new position in Eli Lilly worth $15.7M.

  • Sabby Management's largest Q4 2016 buy was Eli Lilly: 213,113 shares worth $15.7M.
  • Sabby Management added most to Sarepta Therapeutics in Q4 2016, an estimated $59.4M increase.
  • Sabby Management's biggest Q4 2016 reduction was Regenxbio, cutting an estimated $4.1M.
  • Sabby Management fully exited Shire pic in Q4 2016, selling an estimated $6.04M.
  • Sabby Management's ten largest holdings make up 49% of its $1.72B portfolio in Q4 2016.
  • Sabby Management opened 67 new positions and closed 78 in Q4 2016.
  • Sabby Management's portfolio value fell 36% quarter-over-quarter to $1.72B.

Based on Sabby Management's 13F filing for Q4 2016, filed 14 Feb 2017.